Showing posts with label Syndrome. Show all posts
Showing posts with label Syndrome. Show all posts

Tuesday, September 17, 2013

0 Severe dapsone hypersensitivity syndrome in a child













CASE REPORT

Korean J Pediatr 2013 June;56(6) :260-264.
Published online 2012 October 25.        doi:http://dx.doi.org/10.3345/kjp.2013.56.6.260



































Severe dapsone hypersensitivity syndrome in a child
So Yoon Choi1, Ho Yeon Hwang1, Jung Hyun Lee1, Jae Sun Park1, Min Soo Jang2
1Departments of Pediatrics Kosin University Gospel Hospital, Busan, Korea
2Departments of Dermatology, Kosin University Gospel Hospital, Busan, Korea
Corresponding Author: Jae Sun Park ,Tel: +82-51-990-6230, Fax: +82-51-990-3005, Email: pjs@ns.kosinmed.or.kr
Copyright © 2013 by The Korean Pediatric Society
Share :   
ABSTRACT
Dapsone (4,4′-diaminodiphenylsulfone, DDS), a potent anti-inflammatory agent, is widely used in the treatment of leprosy and several chronic inflammatory skin diseases. Dapsone therapy rarely results in development of dapsone hypersensitivity syndrome, which is characterized by fever, hepatitis, generalized exfoliative dermatitis, and lymphadenopathy. Here, we describe the case of an 11-year-old Korean boy who initially presented with high fever, a morbilliform skin rash, generalized lymphadenopathy, hepatosplenomegaly, and leukopenia after 6 weeks of dapsone intake. Subsequently, he exhibited cholecystitis, gingivitis, colitis, sepsis, aseptic meningitis, disseminated intravascular coagulation, syndrome of inappropriate antidiuretic hormone secretion, pneumonia, pleural effusions, peritonitis, bronchiectatic changes, exfoliative dermatitis, and acute renal failure. After 2 months of supportive therapy, and prednisolone and antibiotic administration, most of the systemic symptoms resolved, with the exception of exfoliative dermatitis and erythema, which ameliorated over the following 4 months. Agranulocytosis, atypical lymphocytosis, aseptic meningitis, and bronchiectatic changes along with prolonged systemic symptoms with exfoliative dermatitis were the most peculiar features of the present case.

Keywords: Aseptic meningitis | Bronchiectasis | Dapsone | Multiple organ failure







































TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail



Monday, September 16, 2013

0 Schnitzler"s syndrome: diagnosis, treatment, and follow-up


You have free access to this content

Schnitzler’s syndrome: diagnosis, treatment, and follow-up


Abstract



Schnitzler’s syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long-term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler’s syndrome be suspected? How should the diagnosis of Schnitzler’s syndrome be established? How should a patient with Schnitzler’s syndrome be treated? How should a patient with Schnitzler’s syndrome be followed up?. A diagnosis of Schnitzler’s syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First-line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow-up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.










  1. A. Simon1, 

  2. B. Asli2, 

  3. M. Braun-Falco3, 

  4. H. De Koning4, 

  5. J.-P. Fermand2, 

  6. C. Grattan5,

  7. K. Krause6, 

  8. H. Lachmann7, 

  9. C. Lenormand8, 

  10. V. Martinez-Taboada9, 

  11. M. Maurer6, 

  12. M. Peters10, 

  13. R. Rizzi11, 

  14. F. Rongioletti12, 

  15. T. Ruzicka3, 

  16. L. Schnitzler13, 

  17. B. Schubert14,

  18. J. Sibilia15, 

  19. D. Lipsker8


Article first published online: 9 MAR 2013

DOI: 10.1111/all.12129